Diprosone

Selected form

Medically reviewed

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Diprosone

Diprosone is a prescription-only dermatological medication used for topical application to the skin, containing the single active ingredient Betamethasone Dipropionate. The drug is structurally defined as a synthetic adrenocorticosteroid with a high degree of glucocorticoid activity, used to suppress inflammation and immune responses locally.

Property	Description
Active ingredient	Betamethasone Dipropionate
Forms	Cream, Ointment, Lotion
Pharmacological class	Potent Topical Corticosteroid (Glucocorticoid)
Common use	Relief from inflammation, redness, and itching
Origin	Synthetic

What Type of Medicine is Diprosone?

Diprosone belongs to the pharmaceutical group of glucocorticoids, which are synthetic derivatives of adrenal corticosteroids. As a high-potency agent, the active ingredient is typically rated as a Class III topical corticosteroid in many international systems, positioning it for use when conditions fail to respond adequately to milder treatments. The core function of all such topical corticosteroids involves potent anti-inflammatory, antipruritic, and vasoconstrictive actions, which are clinically recognized for rapidly reducing the visible signs of skin inflammation.

Composition, Forms, and Origin of the Active Ingredient

The medicine is composed of the active substance Betamethasone Dipropionate (INN), a highly modified, synthetic form of the base compound Betamethasone, engineered for optimal dermal absorption. For practical use, the medication is commonly available in several distinct pharmaceutical preparations, specifically a cream, an ointment, and a lotion. The choice of form—such as the oil-based occlusive nature of the ointment for dry lesions versus the lighter, hydrophilic base of the cream—is a key differentiating factor in optimizing ingredient delivery for diverse dermatological presentations.

What is the General Purpose of Diprosone?

The general purpose of this potent medication is to provide rapid and effective symptomatic relief by profoundly controlling inflammatory skin responses. The drug's primary function is to suppress the excessive immune and inflammatory activity within the skin layers, leading to a marked reduction in visible and physical symptoms. This action effectively calms the affected area by minimizing swelling, redness, and the severe itching (pruritus) that defines many inflammatory dermatological conditions.

Regulatory References

FDA/NIH: Betamethasone Dipropionate Monograph

What side effects are possible with Diprosone?

Possible Side Effects and Safety Information

Diprosone, which contains Betamethasone Dipropionate, has an officially documented safety profile characterized by both local skin reactions and the potential for systemic effects from absorption. The safety information is organized by regulatory authorities into frequency categories and affected physiological systems.

Adverse Reactions and System-Organ Classification

Adverse reactions are primarily classified as Skin and Subcutaneous Tissue Disorders. Pruritus (itching), stinging, and burning at the application site are frequently observed and classified as Common in regulatory documentation. Other documented local effects include less common reactions like folliculitis, acneiform eruptions, hypopigmentation, and skin atrophy (thinning).

System-Organ Class	Example Adverse Reaction
Skin and Subcutaneous Tissue Disorders	Folliculitis, Skin Atrophy, Striae
Endocrine Disorders	HPA Axis Suppression, Cushing's Syndrome
Eye Disorders	Cataracts, Glaucoma

Serious Systemic and Population-Specific Considerations

Serious adverse reactions, though generally rare, are linked to the potential systemic absorption of the corticosteroid. These include manifestations of Cushing's syndrome and suppression of the Hypothalamic-Pituitary-Adrenal (HPA) axis, which can lead to adrenal insufficiency. Ophthalmic disorders such as cataracts and glaucoma are also officially documented.

Regulatory labels emphasize that the risk of these serious systemic effects is significantly increased with prolonged or extensive use of the medication. Pediatric patients are officially noted as a high-risk group due to their greater skin surface area-to-body mass ratio, increasing their susceptibility to effects like HPA axis suppression and growth retardation. Furthermore, the medication is contraindicated in the presence of certain untreated infections, such as viral skin infections, and specific conditions like rosacea and perioral dermatitis.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose from Diprosone (Betamethasone Dipropionate) is generally associated with systemic corticosteroid effects following prolonged or excessive application over large surface areas. This excessive absorption may lead to clinical manifestations of Hypercortisolism (Cushing’s syndrome) and, critically, Hypothalamic-Pituitary-Adrenal (HPA) axis suppression.

When to Seek Immediate Medical Help Immediate medical attention is required if there is any suspicion of systemic toxicity or if accidental ingestion of the medicine occurs. Officially, users must seek immediate medical attention upon observing signs consistent with systemic corticosteroid excess. If chronic, excessive use is suspected, medical guidance is necessary, as management often requires the gradual withdrawal of the medicine to prevent acute adrenal insufficiency.

Overdose Management and Specific Risks Management of systemic overdose is officially documented as symptomatic and supportive treatment, including the correction of metabolic imbalances. The regulatory labeling states that no specific antidote is available for systemic toxicity. Pediatric patients are identified as being at higher risk for systemic effects, including HPA axis suppression, growth retardation, and intracranial hypertension, due to their increased surface area to body weight ratio. These serious outcomes necessitate specialized medical monitoring for this population.

Therapeutic Uses of Diprosone

What Diprosone Treats: Main Uses and Benefits

Controlling Severe Inflammatory Skin Conditions

Diprosone is generally used for the symptomatic management of severe or resistant inflammatory dermatoses. This medicine is relevant for conditions involving episodic or fluctuating manifestations, such as plaque psoriasis, various forms of eczema (including atopic and nummular), and other inflammatory conditions like lichen planus. This medicine contributes to easing the overall symptom load associated with core disease manifestations. This medicine is commonly used to help with the discomfort of various skin conditions, including psoriasis and eczema.

Relief from Intense Redness, Swelling, and Itching

The medication is applied in addressing certain distressing symptom clusters of skin flare-ups: pronounced redness (erythema), localized swelling, and particularly severe itching (pruritus). By easing these intense manifestations, the medication assists with maintaining functional stability and supports the management of the itch-scratch cycle. This provides supportive relief that contributes to improved patient comfort and helps ease the overall symptom load on daily stability.

Quick Fact: Relief for Intense Itching
This medication is applied when appropriate when pruritus creates noticeable functional strain, contributing to improved day-to-day comfort during symptomatic periods.

Regulatory References

NIH MedlinePlus overview

Eligibility and Restrictions for Use

Diprosone (betamethasone dipropionate) is a potent topical corticosteroid intended for use in patients with corticosteroid-responsive dermatoses.

Contraindications and Prohibitions

Use of Diprosone is contraindicated in patients with a known hypersensitivity to betamethasone dipropionate, other corticosteroids, or any ingredient in the product. It must not be used to treat certain skin conditions, including rosacea, acne vulgaris, perioral dermatitis, or ulcerative skin lesions. The medicine is also prohibited for use on untreated skin infections caused by viruses (such as herpes simplex, chickenpox, or vaccinia), bacteria, or fungi.

Restricted and Special Populations

Population/Condition	Eligibility Status
Children 12 years and younger	Not recommended for some formulations (e.g., FDA). Use in children must be limited and under strict medical supervision due to higher risk of systemic absorption (HPA axis suppression).
Pregnancy	Use should be limited; not to be used extensively, in large amounts, or for prolonged periods due to potential fetal risk.
Lactation (Breastfeeding)	Caution is advised; a decision to discontinue the drug or nursing should consider the risk to the infant.
Occlusive Use	Prohibited (e.g., under bandages, plastic wraps, or tight-fitting nappies) as it significantly increases systemic absorption.

Long-term use, use over large areas, or application near the eyes is generally not recommended and requires close monitoring.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Diprosone (betamethasone dipropionate) is a topical corticosteroid with generally low systemic absorption; however, specific interactions are documented, primarily concerning the risk of increased systemic exposure and additive effects.

Documented Interaction Categories

Interaction Type	Description and Constraint
Pharmacodynamic Interaction	The concomitant use of Diprosone with other corticosteroid-containing products (topical or systemic) increases the risk of an additive systemic effect, such as HPA axis suppression. Use of such combinations requires medical caution.
Pharmacokinetic Exposure	Medicines known to be potent inhibitors of the enzyme CYP3A4, such as ritonavir and itraconazole, may potentially increase the systemic exposure of absorbed corticosteroids. This necessitates caution in cases of significant percutaneous absorption.

Contextual and Procedural Constraints

The method of application significantly influences the potential for interaction. The use of occlusive dressings or applying the product to large surface areas or broken skin increases percutaneous absorption, which subsequently elevates the risk of systemic exposure and any resulting drug interaction.

Population-Specific Notes: Pediatric patients and individuals with hepatic impairment are identified as populations with a heightened risk of systemic effects from absorbed Diprosone due to their increased susceptibility or reduced drug clearance.

Mechanism of Action

The mechanism of action for Betamethasone Dipropionate is defined by its localized modulation of inflammatory and immune pathways, starting at the cellular level. It functions as a high-affinity agonist for the intracellular Glucocorticoid Receptor ( GR) inside skin cells.

Genomic Repression of Inflammatory Signaling

Upon binding, the drug-receptor complex enters the cell nucleus and alters genetic instructions. It directly suppresses ( transrepresses) pro-inflammatory gene activators, like Nuclear Factor-kappa B ( NF-kappa B), while simultaneously inducing ( transactivates) the production of anti-inflammatory proteins, such as Annexin A1. This modulation reduces the cell's ability to create and release chemical messengers (e.g., cytokines) that sustain certain immune-mediated pathway activity.

Blockade of the Arachidonic Acid Cascade

The induced Annexin A1 protein acts to inhibit the enzyme Phospholipase A2 ( PLA2), effectively blocking the first step in the cascade that generates inflammatory mediators. This blockade prevents the formation of both prostaglandins and leukotrienes, which are mediators associated with increased vascular permeability and afferent nerve activity, resulting in reduced pathway activity within the affected tissues.

Modulation of Local Vascular Response

The drug induces rapid vasoconstriction (narrowing) of the dermal blood vessels. This action, combined with the reduction of chemical mediators that increase vessel leakage, physically limits the flow of blood and the influx of fluid and immune cells into the tissue, resulting in decreased local vascular and cellular activity.

Dosage and Administration Information

How Diprosone is Used: Official Administration Guidelines

The usage of Diprosone (Betamethasone Dipropionate) is strictly governed by its classification as a high-potency topical corticosteroid, requiring adherence to specific administration and duration patterns.

Application and Frequency

Diprosone is intended for dermatologic use only and must never be applied to the eyes, taken orally, or used intravaginally. Application involves gently massaging a thin film of the preparation into the affected area of the skin. The standard dosing schedule is typically once or twice daily, although the frequency should be reduced as the condition improves. For the lotion form, the container must be shaken well prior to use.

Dosing Limits and Duration

The medication is structured for short-term management; therapy should be discontinued immediately when control is achieved, as long-term continuous use is discouraged. To minimize the risk of systemic absorption, the total amount used is restricted, often with a documented maximum of 50 g per week in adult patients for some augmented formulations. Furthermore, official guidelines mandate against covering the application site with occlusive dressings (such as tight bandages or plastic wraps) unless specifically directed, as this significantly increases the absorption of the active ingredient.

Population and Area Restrictions

Specific restrictions apply to vulnerable groups and sensitive body areas. Application to the face is typically limited to no more than 5 consecutive days. For children under 13 years, the duration of treatment is restricted, often limited to a maximum of 5 days, to mitigate the potential for systemic effects. The preparation should not be applied to skin that is cut, scraped, or otherwise damaged.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Diprosone

The research for Diprosone (Betamethasone Dipropionate) focuses on what was studied in clinical settings. Studies are primarily designed to explore short-term changes in outcomes related to specific inflammatory skin conditions. The overall evidence landscape consists mainly of randomized controlled trials (RCTs), which compare the medicine against an inactive cream (vehicle) or against other existing topical treatments, allowing researchers to observe responses over defined time intervals.

Evidence for Use in Severe or Resistant Plaque Psoriasis

Research exploring short-term changes in outcomes related to severe or resistant plaque psoriasis has utilized a number of Randomized Controlled Trials (RCTs). These studies typically involved adults and adolescents with stable forms of the condition. Researchers focused on outcomes related to physical discomfort by measuring changes in the size, thickness, and redness of the plaques, often used validated tools such as the Psoriasis Area and Severity Index (PASI) and the Investigator's Global Assessment (IGA) scale.

Research examining long-term outcomes remains limited, and follow-up durations were limited in the primary controlled trials. The available research provides limited information on how the condition evolves over many months or years of observation, and the study results apply primarily to the specific stable, mild-to-moderate psoriasis populations that were included.

Evidence for Use in Atopic Dermatitis (Eczema)

Research for atopic dermatitis (eczema), a condition characterized by fluctuating or episodic manifestations, also relies on short-term RCTs and comparative trials. These studies were conducted in research scenarios exploring short-term symptom changes, focusing on episodes where symptoms become more noticeable, such as acute flare-ups. Studies monitored patient-reported outcomes describing perceived discomfort, specifically severe itching (pruritus), alongside objective signs like erythema and swelling.

Furthermore, while research was evaluated in children, studies also monitored outcomes related to systemic or functional imbalance (such as the HPA axis) as a specific area of focus, particularly in younger populations. The existing evidence is primarily focused on research scenarios exploring acute changes. Long-term effects are not fully established.

Research Gaps and What Remains Uncertain

The majority of data reviewed in support of the medicine's use comes from short-term follow-up durations (typically weeks, not months). Long-term effects are not fully established, and there is limited information about the long-term management of conditions using this medicine. Comparative evidence against other treatments is lacking in some subgroups. The study results reflect the specific conditions under which they were conducted, and certainty remains low for use over extended durations.

Key Studies & References

NICE Guideline NG136: Atopic eczema in under 16s: management

Frequently Asked Questions (FAQ)

Common questions about Diprosone (FAQ)

Q: Does using this cream/ointment increase my blood sugar (glucose) levels?

A: Topical corticosteroids, including Diprosone, can be absorbed through the skin into the body. Official regulatory documents indicate that absorbed corticosteroids have been associated with reports of hyperglycemia (high blood sugar) and glucosuria (sugar in the urine) in certain patients.

Q: Can I use the cream/ointment for conditions other than eczema and psoriasis, such as bug bites?

A: The medicine is indicated for the relief of inflammation, redness, and itching associated with corticosteroid-responsive dermatoses. The product information states that the medicine is specifically contraindicated (prohibited for use) for certain conditions, including fungal infections like ringworm (tinea) and most viral skin infections, such as those caused by the herpes simplex virus.

Q: Can this medication cause a change in my skin color?

A: Yes, official regulatory documents list changes in skin color as a possible local adverse reaction. Specifically, hypopigmentation—a lightening of the skin color in the treated area—has been reported as a documented side effect.

Q: Can I use the cream/ointment if I have acne?

A: Official information states that Diprosone is contraindicated (prohibited for use) for treating conditions such as acne vulgaris (common acne) or acne rosacea. Furthermore, 'acneiform eruptions,' which are lesions that resemble acne, are listed as a possible adverse reaction from using the product.

Q: Is this drug considered a fluorinated corticosteroid?

A: Yes, in official product descriptions and pharmacology reviews, the active ingredient, betamethasone dipropionate, is chemically defined as a fluorinated corticosteroid. This term relates to its specific chemical structure.

Q: Is it possible to develop an allergy to this medicine while using it?

A: The medication is contraindicated if a known hypersensitivity (allergy) already exists to the active ingredient or other components of the preparation. Official safety information also documents that allergic contact dermatitis, which is a form of skin reaction, has been reported as an adverse reaction.

Q: Is this drug on the WADA Prohibited List for athletes?

A: Glucocorticoids, the class of medicine Diprosone belongs to, are generally prohibited for athletes during competition when taken by oral, injectable, or rectal routes. According to official sporting authority documents, topical (skin) applications are generally not prohibited.

Q: Does the drug absorb more through damaged skin (like eczema) than healthy skin?

A: Official warnings state that the amount of medication absorbed into the body is influenced by the condition of the skin barrier. Inflammation, active disease processes in the skin, or use on broken skin are all factors that are described as increasing the rate of percutaneous (through the skin) absorption.

Q: Are there specific precautions for use in older adults?

A: Official product information does not generally provide separate, specific cautions or dosage adjustments for the general older adult population. Special warnings are predominantly focused on pediatric patients and those with risk factors for increased systemic absorption.

Q: Is the risk of skin thinning different for children compared to adults?

A: Regulatory documents include specific warnings for children. Due to their greater ratio of skin surface area to body mass, children are considered more susceptible to both systemic toxicity and local side effects like skin atrophy (thinning) when compared to adults. For this reason, official guidelines emphasize limited use and duration of treatment in children.

Q: Is the lotion form better for areas like the scalp or hairy skin?

A: Official product information indicates that the lotion formulation is specifically indicated for use in certain types of eczema, dermatitis, and psoriasis that affect the scalp.

How should Diprosone be stored and disposed of?

To ensure Diprosone maintains its integrity, store the product in a closed container at Controlled Room Temperature, generally between 20 C and 25 C (68 F and 77 F). The product must be protected from freezing and excessive heat. Diprosone Lotion and some forms require protection from light.

Always keep this medicine out of the sight and reach of children. Do not use the medicine after the expiration date (EXP) shown on the packaging. To dispose of unused or expired medicine, do not throw it away in household trash or flush it down the toilet; instead, ask a pharmacist or healthcare provider about medicine take-back options or local disposal guidelines. Note that fabrics like bedding or clothing that have been in contact with the product may pose a serious fire hazard.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.